Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab in Relapsed Aggressive Non-Hodgkin's Lymphoma
NCT00016094Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2001
- Primary completion
- Aug 2005
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in non-Hodgkin lymphoma (NHL), sponsored by National Cancer Institute. Primary endpoint: Progression-free survival rate at 6 months. Started Apr 2001; status: completed.
02
Drugs
bevacizumab
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00016094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00016094.